Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-599-9 | CAS number: 7647-15-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Specific investigations: other studies
Administrative data
Link to relevant study record(s)
Description of key information
In a 12 week study in humans a significant increase in serum thyroxine and triiodothyronine was observed between the start and end of the study for the 9 mg(Br-)/kg bw/day dose group females but remained within normal limits at all concentrations. No changes were observed in measurements of hormones produces by the adrenals, the gonads and the pituitary gland.
Given the hormone changes observed, despite that fact that they are considered to remain within normal limits, a precautionary LOAEL of 9 mg(Br-)/kg bw/day has been determined. The NOAEL from this study is therefore 4 mg(Br-)/kg bw/day.
Additional information
The lowest LOAEL was obtained in a 12 week study in humans (Van Gelderen et al., 1993):
No findings of clinical effects relevant to the investigation were found, except for some incidences of nausea associated with bromide-capsule ingestion.Haematological, clinical chemistry and urine analysis parameters remained within normal limits for all dose groups.
A significant increase in serum thyroxine and triiodothyronine between the start and end in the study for the 9 mg(Br-)/kg bw/day dose group females but all concentrations remained within normal limits. No changes were observed in measurements of hormones produces by the adrenals, the gonads and the pituitary gland.
All neurophysiological findings were within normal limits.
Given the hormone changes observed, despite that fact that they are considered to remain within normal limits, a precautionary LOAEL of 9 mg(Br-)/kg bw/day has been determined. The NOAEL from this study is therefore 4 mg(Br-)/kg bw/day.
A lower NOAEL of 1 mg(Br-)/kg bw/day was found in a shorter (8 week) human volunteer study, however, only one dose was assessed in this study and no LOAEL was determined.
An additional 12 week in humans study concluded that the NOAEL is 9 mg(Br-)/kg bw/day. Given that a LOAEL has been determined at this dose the NOAEL was not used.
In summary:
LOAEL: 9 mg(Br-)/kg bw/day - hormone level alterations in females.
NOAEL: 4 mg(Br-)/kg bw/day.Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.